Regeneron Pharmaceuticals, Inc.
General ticker "REGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $65.2B (TTM average)
Regeneron Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 29.0%.
Estimated limits based on current volatility of 1.9%: low 734.85$, high 763.68$
Factors to consider:
- Earnings expected soon, date: 2026-01-30 bmo
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Company pays dividends (quarterly): last record date 2025-11-20, amount 0.88$ (Y0.48%)
- Total employees count: 15106 (+12.3%) as of 2024
- US accounted for 8.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key products, Labor/talent shortage/retention, Cybersecurity threats, Public health crises, Geopolitical risks
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [671.44$, 992.05$]
- 2025-12-31 to 2026-12-31 estimated range: [708.08$, 1030.19$]
Financial Metrics affecting the REGN estimates:
- Negative: with PPE of 15.6 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 28.21 > 18.33
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: 0.01 < Interest expense per share per price, % of 0.07
- Negative: Investing cash flow per share per price, % of -3.22 <= -0.62
- Negative: negative Industry operating cash flow (median)
- Negative: Operating cash flow per share per price, % of 5.76 <= 6.63
- Positive: Shareholder equity ratio, % of 77.74 > 64.17
Short-term REGN quotes
Relationship graph
Long-term REGN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $12,262.80MM | $13,119.30MM | $14,148.60MM |
| Operating Expenses | $7,523.90MM | $9,072.20MM | $10,157.90MM |
| Operating Income | $4,738.90MM | $4,047.10MM | $3,990.70MM |
| Non-Operating Income | $119.90MM | $152.20MM | $789.20MM |
| Interest Expense | $59.40MM | $73.00MM | $55.20MM |
| R&D Expense | $3,847.60MM | $4,625.10MM | $5,233.00MM |
| Income(Loss) | $4,858.80MM | $4,199.30MM | $4,779.90MM |
| Taxes | $520.40MM | $245.70MM | $367.30MM |
| Profit(Loss)* | $4,338.40MM | $3,953.60MM | $4,412.60MM |
| Stockholders Equity | $22,664.00MM | $25,973.10MM | $29,353.60MM |
| Inventory | $2,401.90MM | $2,580.50MM | $3,087.30MM |
| Assets | $29,214.50MM | $33,080.20MM | $37,759.40MM |
| Operating Cash Flow | $5,014.90MM | $4,594.00MM | $4,420.50MM |
| Capital expenditure | $590.10MM | $926.40MM | $755.90MM |
| Investing Cash Flow | $-3,784.60MM | $-3,185.10MM | $-2,468.10MM |
| Financing Cash Flow | $-1,009.00MM | $-1,790.10MM | $-2,200.50MM |
| Earnings Per Share** | $40.51 | $37.05 | $40.90 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.